Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05502198Recruiting
How muscle loss matters in advanced liver disease
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
EksjöAges 18 years+ - NCT05534906Recruiting
Detecting very early liver cancer and tracking its natural course
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Oxford, OxfordshireAges 18–100 - NCT05541601Recruiting
Study to detect liver cancer early in people with cirrhosis
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Oxford, OxfordshireAges 18–100 - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05794048Recruiting
Study of blood and tumor features in liver and pancreatic cancers
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
ClichyAges 18 years+ - NCT05803928RecruitingPhase 1
Ablation plus lenvatinib and anti-PD-1 to prevent liver cancer return
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
Guangzhou, GuangdongAges 18–75 - NCT06007846RecruitingPhase 2/Phase 3
Memantine for advanced liver cancer and cirrhosis
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
Fairfax, VirginiaAges 18 years+ - NCT06015022RecruitingPhase 2
Green tea extract to prevent liver cancer in cirrhosis
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
Dallas, TexasAges 18 years+ - NCT06345508Recruiting
Finding liver cancer early with ultrasound
This study tests a new ultrasound technique to catch liver cancer sooner. If you have regular imaging checks for liver cancer or are getting an MRI for a liver spot, you may be able to join.
Montreal, QuebecAges 18 years+ - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06492408RecruitingPhase 2
Immunotherapy before surgery for liver cancer
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT06518434RecruitingPhase 2
Cannabis oil for advanced liver cancer study
This study tests if cannabis oil can help people with advanced liver cancer that cannot be treated with standard therapies. It is a small pilot study to see if the oil is safe and may improve symptoms or quality of life.
GroningenAges 18 years+ - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT06718153Recruiting
Using protein tests to diagnose liver cancer types
This trial uses special stains on tumor tissue to find genetic changes in liver cancer cells. It may help doctors better diagnose and classify the type of liver cancer you have.
BolognaAges 18 years+ - NCT06777628Recruiting
Blood test study to predict immunotherapy success in liver cancer
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
Bologna, Laura GramantieriAges 18 years+ - NCT07142213Recruiting
Studying a two-step liver surgery for liver cancer
This trial looks at a special two-step surgery called ALPPS for people with liver cancer that can't be removed in one operation. The first step helps the liver grow more healthy tissue, and then the second step removes the tumor. The goal is to understand how well this works and how the liver regenerates.
Beijing, Beijing MunicipalityAges 18–75 - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT02081755Enrolling by invitationPhase 4
Everolimus after liver transplant to lower liver cancer return
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
San Francisco, CaliforniaAges 18 years+ - NCT07560566RecruitingPhase 2
Preventing Hand-Foot Skin Reaction in Liver Cancer Treatment
This study tests whether a topical anti-inflammatory cream (indomethacin) applied preventively to hands and feet can reduce a painful skin side effect called hand-foot syndrome that occurs in advanced liver cancer patients taking sorafenib. If effective, it could help patients tolerate their cancer medication better.
TaipeiAges 18 years+ - NCT07290764Enrolling by invitation
Surgery vs observation for liver cancer that responded to drug therapy
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
Fuzhou, FujianAges 18–75 - NCT07052448Enrolling by invitation
Radiation after triple therapy for liver cancer
This trial tests whether adding radiation therapy after a combination of three treatments (like immunotherapy and targeted therapy) can help people with liver cancer that cannot be surgically removed. It may be a good option if your tumor responded to the triple therapy but you still cannot have surgery.
Fuzhou, FujianAges 18–75 - NCT05412589RecruitingPhase 2
Testing three cancer medicines for advanced liver cancer
This trial studies how well a combination of chemotherapy, immunotherapy, and an anti-angiogenesis medicine works for advanced hepatocellular carcinoma (HCC), a type of liver cancer. It may help slow tumor growth and improve outcomes by attacking cancer in different ways.
Guangzhou, GuangdongAges 18–75
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 484 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.